Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07512323

Effect of Testosterone on Elderly Frail Men With Testosterone Deficiency

The purpose of this study is to increase the functional level of the elderly to thereby reduce fall risk, improve motor skills, and increase psychological well-being, as well as to assess whether the restoration of a normal testosterone level contributes to a faster recovery. The effect of testosterone is investigated as measured by physical and mental functional capacity, including cognition, in hypogonadal elderly men with a significant loss of function. The study is aimed at participants who are too weak to participate in the progressive strength training.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Frail Elderly Patients Endocrine System Diseases Falls (Accidents) in Old Age Frailty Gonadal Disorders Hypogonadal Males Hypogonadism Pathologic Processes Pathological Conditions, Signs and Symptoms Testosterone Replacement Therapy

Age range

70 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 2

Primary location

About this study

Please see the uploaded study protocol.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men aged 70 or over.
  • Living at home in their own home or in sheltered housing.
  • Independent walking function, possibly with a walking aid.
  • Able to perform the chair-stand test a maximum of 8 times in 30 seconds or Timed Up and Go (TUG) of at least 30 seconds.
  • There must be at least 3 symptoms of frailty or objective findings.
  • Serum testosterone < 10 nmol/L as an average of 2 independent measurements at the Center for Growth and Reproduction, Rigshospitalet.

Exclusion criteria

  • Known or previous prostate cancer.
  • Abnormally elevated serum PSA (PSA = prostate-specific antigen) corresponding to PSA > 5 ng/ml or PSA > 0.15 ng/ml/cc (relative to prostate size in cubic centimeters (cc)).
  • Hemochromatosis.
  • Heart diseases in the form of: Peri-, myo-, or endocarditis, angina pectoris, severe heart failure (NYHA class III and IV), severe hypertension (systolic BP > 180 or diastolic BP > 105 mmHg after possible antihypertensive treatment). - Resting dyspnea.
  • Liver (ASAT > 2 x upper normal limit) or renal insufficiency (serum creatinine > 200 micromol/l).
  • Severe intractable epilepsy or migraine.
  • Insulin treatment.
  • Previous or current bisphosphonate, fluoride, HRT, SERM, strontium, teriparatide, or more than 3 weeks of prednisolone treatment.
  • Joint disease with acute inflammation.
  • Active cancer disease, in chemo- or radiotherapy.
  • Bone metabolic disease except for age-related osteoporosis.
  • Autoimmune diseases, chronic systemic diseases (cirrhosis, AIDS, chronic renal failure).
  • Primary testosterone deficiency in the form of testicular dysgenesis, Klinefelter syndrome (47,XXY), 46,XX males, LH resistance, Y chromosome deletions, other sex chromosome abnormalities.
  • Significant abuse, mental illness, dementia, physical handicaps with inability to complete the intervention or tests, or to give informed consent.
  • Contraindications for testosterone undecanoate are thus included in exclusion criteria, such as the presence of liver tumors, breast carcinoma, and prostate cancer, for which trial participants will be examined before the start of the trial.

Treatment and study plan

Nebido (Testosterone Undecanoate)

Drug

Testosterone supplementation is given intramuscularly with 1000 mg testosterone undecanoate, which has an effect for approx. 12 weeks, but which can be repeated more frequently between the 1st and 2nd administration. The injection is thus repeated in week 6. 3 injections per trial subject are expected, i.e., in weeks 1, 6, and 16.

If the participants are motivated to continue so that long-term effects can be measured, the participants will be asked in week 12 whether they wish to continue to week 52. Upon acceptance of continuation to week 52, testosterone and placebo injections are offered according to original groups in weeks 26, 36, and 46, after which testing of primary and secondary endpoints is not only performed in week 20 but also in week 52.

Other names: Intervention, Experimental

Primary outcomes

  1. Chair-stand test

    Time frame: At weeks 0, 4 and 20.

    A measure of general strength in extremities. Number of times the participant can stand up and sit down from a chair in 30 seconds. A good correlation (r=0.78) has been found with leg press and acceptable test-retest reliability (ICC=0.86). It has recently been scientifically documented that the ability among elderly persons to perform this simple test correlates with the risk of serious fall accidents

Secondary outcomes

  1. Measurement of fall frequency and severity

    Time frame: At weeks 0, 4 and 20.

    Registered via a questionnaire for each trial subject and is also included in the monitoring of adverse events.

  2. Balance ability

    Time frame: At weeks 0, 4 and 20.

    Tested via the Tandem test, which contains three starting positions: 1) Standing with feet together, standing in semi-tandem stance, and standing in tandem stance.

  3. Avlund's mobility scale

    Time frame: At weeks 0, 4 and 20.

    Questions about experiencing fatigue and need for support in common activities of daily living. Avlund's mobility scale is correlated with isometric muscle strength, simple functional tests, increased risk of hospitalizations, and mortality. Good inter- and intra-reliability (kappa 0.72-1.00) has been shown. Scores range from 0 to 6, and higher scores indicate worse outcome.

  4. Geriatric Depression Scale (GDS)

    Time frame: At weeks 0, 4 and 20.

    Questionnaire about depression and psychological well-being. Scores range from 0 til 15. Score below 5 are normal, while scores of 5 or higher indicate varying degrees of depression, scoring 13-15 indicates severe depression.

  5. Montreal Cognitive Assessment (MoCA)

    Time frame: At weeks 0, 4 and 20.

    The Montreal Cognitive Assessment is a cognitive screening instrument which provides an estimate of the level of intellectual functioning. Scores are from 0 to 30, where a score of 26 or higher is considered normal. Montreal Cognitive Assessment is moreover sensitive to mild cognitive problems as well as dementia. Studies have shown that Montreal Cognitive Assessment is more sensitive than Mini Mental State Examination to detecting mild cognitive changes and is as effective in identifying the incidence of Alzheimer's disease.

  6. Mini Mental State Examination (MMSE)

    Time frame: At weeks 0, 4 and 20.

    Cognitive screening test that provides an estimate of the intellectual functional level. This test is included as it is performed as standard at the Geriatric Outpatient Clinic. Combined, MMSE and MoCA provide a broader assessment of cognitive functional level. Scores range from 0 to 30, higher scores indicate better cognitive status. Scores from 26 to 30 are considered normal.

  7. Quality of life EQ-5D

    Time frame: At weeks 0, 4 and 20.

    Questionnaire about perceived quality of life. Scores range from 0 to 1 (first scale) and from 0 to 100 (second scale). Higher scores indicate better quality of life.

  8. Clinical Frailty Scale (CFS)

    Time frame: At weeks 0, 4 and 20.

    General assessment of health and functional level in the elderly. Scoring ranges from 1 to 9, and higher scores indicate more frailty.

  9. Falls Efficacy Scale - International (FES-I, Fear of falling). Scores range from 16 to 64, and higher scores indicate increased anxiety of having a severe fall accident.

    Time frame: At weeks 0, 4 and 20.

    Assessment of fall risk in the elderly.

Study contacts

Contact information is provided by the study sponsor or research team.

Karsten Overgaard, MD, Neurologist

CONTACT

[email protected]

26172611

Rune S. Rasmussen, MSc, PhD

CONTACT

[email protected]

+4528757500

Sponsors and collaborators

Lead sponsor

Rune Skovgaard Rasmussen

Other

Registry information

Official study title

Effect of Testosterone on Elderly Frail Men With Testosterone Deficiency - a Double-blinded, Randomized and Placebo-controlled Intervention Study

Important dates

Study start
2026
Primary completion
2029
Study completion
2030
First posted
Apr 6, 2026
Registry last updated
May 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.